Scancell Holdings PLC · LSE:SCLP
Scancell — Shareholder Meeting (September 2019)
18 slides from Scancell's shareholder meeting presentation, Sep 12, 2019
Slide 1: SCANCELL AGM presentation
SCANCELL AGM presentation 12 September 2019 Dr Cliff Holloway – CEO Dr Sally Adams – Development Director Professor Lindy Durrant – CSO LSE: SCLP.L A NEW FRONTIER IN IMMUNO-ONCOLOGY
Slide 2: Disclaimer
DISCLAIMER The information contained in these slides has been prepared by Scancell Holdings plc (the "Company"). It has not been approved by the United Kingdom Financial Conduct Authority under the Prospectus Rules (made under Part VI of the Financial Services and Markets Act 2000) or otherwise, or
Slide 3: Development Pipeline
DEVELOPMENT PIPELINE IMMUNOBODY® MODITOPE® AvidiMab™ / TaG mAbs SCIB1: Targets malignant melanoma. Phase 2 Modi-1: Phase 1/2 trial including breast, ovarian, Anti-glycan mAbs: Monoclonal antibodies trial in patients receiving immune checkpoint and head & neck cancer planned for 1H CY20 (mAbs)
Slide 4: Oncology Partnering Trends
ONCOLOGY PARTNERING TRENDS Drug development is inherently shaped and enabled by strategic partnerships Strategic consolidations provide a significant source of new pipeline drugs for big pharma/biotech companies Pooling resources increase the chances of successfully developing promising candid
Slide 5: Commercial Positioning
COMMERCIAL POSITIONING Three Pillars Supporting the Path to Commercial Success Defined Product Value Execution/Resource Planning Partner Search Criteria ► Target Product Profile ► Building on core research ► First or best in class ► Impact on patient survival and development (differentiated Tx targe
Slide 6: ImmunoBody: SCIB1 / SCIB2
IMMUNOBODY: SCIB1 / SCIB2 Defining Product Value Enhanced Capabilities Meeting Search Criteria ► Phase 1/2 clinical data ► Manufacturing expertise ► Differentiated approach to demonstrates safety and ► Regulatory process known antigens efficacy as monotherapy ► Clinical network (CRUK) ► Demonstrated
Slide 7: Moditope: Modi-1 / Modi-2 / TCR
MODITOPE: Modi-1 / Modi-2 / TCR Defining Product Value Enhanced Capabilities Meeting Search Criteria ► Modi-1 Phase 1/2 clinical ► Manufacturing expertise ► Novel targets (siPTM) study planned to define ► Clinical Advisory Board safety and efficacy as a ► Unique MoA (cytotoxic (CAB) CD4 T-cell) mono
Slide 8: Monoclonal Antibodies: TaG mAbs / AvidiMab
MONOCLONAL ANTIBODIES: TaG mAbs / AvidiMab™ Defining Product Value Enhanced Capabilities Meeting Search Criteria ► Tumour associated ► Legacy research ► Novel mAb targets glycans (TaGs) unique capabilities (NUTAC) targets ► Unique MoA ► Know-how for generating ► Direct cell killing mAbs against TAGs
Slide 9: Development Update
DEVELOPMENT UPDATE A NEW FRONTIER IN IMMUNO-ONCOLOGY 9
Slide 10: SCIB1-002 Clinical Study – US vs UK
SCIB1-002 CLINICAL STUDY – US vs UK ► Key drivers for initial US vs UK decision ► Visibility in US ► Enthusiasm of US investigators and availability of patients ► Reimbursement of Keytruda costs by US healthcare providers; no equivalent in UK ► Need open IND and UK approval to open a site under an I
Slide 11: SCIB1-002 Clinical Study – US vs UK
SCIB1-002 CLINICAL STUDY – US vs UK ► UK regulatory submissions approved ► MHRA clinical trials division for drug safety ► MHRA devices division for TDS-IM device safety ► HRA – Health Research Authority for ethics and site approvals ► Delay in FDA resolution of device issues led to re-evaluation of
Slide 12: Modi-1 Development
MODI-1 DEVELOPMENT THREE DRUG SUBSTANCES = MODI-1 DRUG PRODUCT ► Modi-1 conjugates - novel cutting-edge products Vimentin 415 peptide ► Hydrophobic peptides ► Challenging synthetic properties ► Manufacturing ► Analytical development Vimentin 28 peptide ► Polypeptide Group (PPL) selected as GMP manuf
Slide 13: Modi-1 Development Progress
MODI-1 DEVELOPMENT PROGRESS ► Development batches of three Drug Substances completed ► To supply material for preclinical toxicity and stability studies ► Formulation and analytical work ► GMP manufacture of three Drug Substances ongoing ► Formulation development underway at AMRI ► Soluble formu
Slide 14: Research Update
RESEARCH UPDATE A NEW FRONTIER IN IMMUNO-ONCOLOGY 14
Slide 15: Research
RESEARCH ► Modi-2: homocitrullination of lysine residues – PCT filed 9-9-19 ► Screened 18 peptides using new algorithm ► 18 stimulated T cell responses ► 5 gave strong anti-tumour responses ► TCR ► Project delayed due to requirement for Health and Safety Approval (HSE) ► Lenti-viral transduction of
Slide 16: Glycome
GLYCOME ► Glycans are expressed on a wide variety of molecules ► Multiple sugars which can be linked in any order to give a glycan ► Sugars can be branched ► Sugars are linked by glycosyltransferase enzymes ► These enzymes can be up or down regulated in cancer creating unique targets ► The same glyc
Slide 17: Targeting Tumour-Associated Glycans - TaGs
TARGETING TUMOUR-ASSOCIATED GLYCANS - TaGs Five new anti-glycan antibodies ► IgG mAbs with sub-nanomolar functional affinity ► Ultraspecific to unique tumour-associated glycans (TaGs) ► Low expression on a limited number of normal tissues ► Can kill by direct membrane damage ► Can also induce potent
Slide 18: AvidiMab
AvidiMabTM Technology to enhance the avidity of any mAb ► Non-covalent association at the cell surface ► Induces direct killing with glycolipid targets ► Works on cold tumours (no immune response) ► Does not prevent ADCC/CDC ► Pharma/Biotechs could license the platform to enhance the potency of thei
Scancell Holdings — Shareholder Meeting (September 2019) on 6ix